The estimated Net Worth of Management Corp Harbert Dis... is at least $7.84 millió dollars as of 15 March 2021. Management Dis owns over 444,768 units of Enzo Biochem stock worth over $5,745,263 and over the last 5 years Management sold ENZ stock worth over $2,094,857.
Sign up
Management Dis ENZ stock SEC Form 4 insiders trading
Management has made over 5 trades of the Enzo Biochem stock since 2019, according to the Form 4 filled with the SEC. Most recently Management sold 444,768 units of ENZ stock worth $2,094,857 on 15 March 2021.
The largest trade Management's ever made was selling 444,768 units of Enzo Biochem stock on 15 March 2021 worth over $2,094,857. On average, Management trades about 202,472 units every 133 days since 2019. As of 15 March 2021 Management still owns at least 5,175,913 units of Enzo Biochem stock.
You can see the complete history of Management Dis stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Enzo Biochem
Over the last 22 years, insiders at Enzo Biochem have traded over $2,615,763 worth of Enzo Biochem stock and bought 1,070,494 units worth $3,103,461 . The most active insiders traders include Bradley Louis Radoff, Management Corp Harbert Dis... és Elazar Rabbani. On average, Enzo Biochem executives and independent directors trade stock every 127 days with the average trade being worth of $59,099. The most recent stock trade was executed by Kara Cannon on 21 February 2024, trading 10,640 units of ENZ stock currently worth $11,810.
What does Enzo Biochem do?
enzo biochem inc is a financial services company located in 60 executive blvd, farmingdale, new york, united states.
What does Enzo Biochem's logo look like?
Complete history of Management Dis stock trades at Enzo Biochem
Enzo Biochem executives and stock owners
Enzo Biochem executives and other stock owners filed with the SEC include:
-
Elazar Rabbani,
Chairman of the Board, Chief Executive Officer, Secretary -
Barry Weiner,
President, Treasurer -
Dr. Elazar Rabbani Ph.D.,
Co-Founder, Chairman, Chief Scientific Officer & Sec. -
Barry W. Weiner,
Founder, Treasurer & Pres -
Dieter Schapfel,
Chief Medical Director - Enzo Clinical Labs -
Kara Cannon,
Chief Commercial Officer -
Dr. Dieter Schapfel M.D.,
Chief Medical Director of Enzo Clinical Labs -
David Bench,
Chief Financial Officer, Principal Accounting Officer -
David A. Bench,
CFO & Principal Accounting Officer -
Dov Perlysky,
Lead Independent Director -
Rebecca Fischer,
Independent Director -
Ian Walters,
Independent Director -
Mary Tagliaferri,
Independent Director -
Kara Cannon,
Chief Commercial Officer -
Hamid Erfanian,
CEO & Director -
Bruce A. Dey,
VP of Sales & Marketing - Enzo Clinical Labs -
Gregory M. Bortz,
Director -
Bernard L Kasten,
Director -
David C Goldberg,
VP CorpDev Pres Enz Clin Labs -
Steven J Pully,
Director -
Bruce A. Hanna,
Director -
James Michael O'brien,
EVP of Finance -
Peter J Iv Clemens,
10% owner -
Management Corp Harbert Dis...,
-
Stanford S Warshawsky,
Director -
Fabian Blank,
Director -
Christine Fischette,
Pres., Enzo Therapeutics, Inc. -
Irwin Gerson,
Director -
John Delucca,
Director -
Stephen B H Kent,
Director -
Dean Engelhardt,
Executive Vice President -
Melvin F Lazar,
Director -
Barbara E Thalenfeld,
VP Corporate Development -
John B Sias,
Director -
Carl W Balezentis,
Pres., Enzo Life Sciences -
Kevin Krenitsky,
President, Enzo Clinical Labs -
Shahram K Rabbani,
COO, Treasurer & Secretary -
Norman E Kelker,
Senior Vice President -
Herbert B Bass,
VP of Finance -
Andrew P Whiteley,
VP BusDev-COO Enzo Lif Sci Inc -
Bradley Louis Radoff,
Director -
James G. Wolf,
-
Hamid Erfanian,
Chief Executive Officer -
Patricia Eckert,
Chief Financial Officer